BRCA2 and prostate carcinoma: The risk of prostate cancer in male carriers of BRCA1 variants is approximately equivalent to the general population’s risk, but the phenotype of such cancers, as well as the therapeutic approach, is similar to that of carriers of BRCA2 variants.